RADX · Radiopharm Theranostics Limited American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RADX by emailGet an email when RADX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RADX, unsubscribe in one click. Privacy
📣 What RADX Says Is Next
by year-end · ““We believe the upcoming discussion will provide important alignment on the clinical and regulatory pathway forward, enabling us to finalize plans for a registrational study and remain on track to be Phase 3-ready by year-end.”
Company press release, Aug 17, 2026 · SEC filing
2H 2026 · “RAD 301 has previously received Orphan Drug Designation (ODD) from the FDA and data from the Phase 1 trial is supportive of the Company’s decision to move to a Phase 2 imaging trial in patients with loco-regional pancreatic cancer. · Enrollment in the Phase 1 imaging trial in metastatic pancreatic cancer continues, having dosed 8 patients out of 9, with last patient expected to be dosed in 2H 2026.”
Company press release, Jul 31, 2026 · SEC filing
Q4 2026 · “The Company anticipates the initiation of a Phase 3, multi-center, multi-country registrational study in Q4 2026.”
Company press release, Jul 31, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RADX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RADX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.